CHUGAI PHARMACEUTICAL CO., LTD. Logo

CHUGAI PHARMACEUTICAL CO., LTD.

An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.

4519 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
北区浮間五丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chugai Pharmaceutical Co., Ltd. is a research and development-oriented pharmaceutical company and a member of the Roche Group. The company specializes in creating innovative prescription drugs to address unmet medical needs, leveraging its unique science and proprietary antibody engineering technologies. Chugai's growth strategy is driven by a shift towards discovery research and early clinical development, the application of digital technology (DX) across its value chain, and open innovation through external partnerships. It is a leading presence in the Japanese therapeutic antibody market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-25 08:42
Interim Report
確認書
Japanese 9.6 KB
2025-07-25 08:40
Interim Report
半期報告書-第115期(2025/01/01-2025/12/31)
Japanese 298.8 KB
2025-04-22 09:07
Regulatory News Service
訂正臨時報告書
Japanese 39.1 KB
2025-03-28 06:43
Post-Annual General Meeting Information
臨時報告書
Japanese 27.8 KB
2025-03-27 08:12
Regulatory News Service
臨時報告書
Japanese 39.7 KB
2025-03-27 07:57
Governance Information
内部統制報告書-第114期(2024/01/01-2024/12/31)
Japanese 24.8 KB
2025-03-27 07:50
Registration Form
確認書
Japanese 9.6 KB
2025-03-27 07:48
Annual Report
有価証券報告書-第114期(2024/01/01-2024/12/31)
Japanese 3.3 MB
2024-07-26 08:02
Regulatory News Service
確認書
Japanese 9.6 KB
2024-07-26 08:01
Interim Report
半期報告書-第114期(2024/01/01-2024/12/31)
Japanese 330.6 KB
2024-07-26 07:35
Regulatory News Service
確認書
Japanese 9.6 KB
2024-07-26 07:30
Regulatory News Service
訂正有価証券報告書-第113期(2023/01/01-2023/12/31)
Japanese 1.8 MB
2024-04-25 08:09
Regulatory News Service
確認書
Japanese 9.6 KB
2024-04-25 08:07
Quarterly Report
四半期報告書-第114期第1四半期(2024/01/01-2024/03/31)
Japanese 272.0 KB
2024-04-24 08:21
Registration Form
確認書
Japanese 9.6 KB

Automate Your Workflow. Get a real-time feed of all CHUGAI PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CHUGAI PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France BIM
BioPorto Logo
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
Denmark BIOPOR
Biosergen AB Logo
Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.
Sweden BIOSGN
Bio Solution Co.,Ltd. Logo
Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.
South Korea 086820
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France ALBIO
Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany BIO3
Biotika A.S. Logo
Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.
Slovakia BSL
Bioton S.A. Logo
Develops and manufactures recombinant human insulin for global diabetes care solutions.
Poland BIO
BIOVENTIX PLC Logo
Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.
United Kingdom BVXP
Bioversys N Logo
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
Switzerland BIOV

Talk to a Data Expert

Have a question? We'll get back to you promptly.